<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01669876</url>
  </required_header>
  <id_info>
    <org_study_id>RCP-009</org_study_id>
    <nct_id>NCT01669876</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease</brief_title>
  <acronym>ASAP</acronym>
  <official_title>3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rock Creek Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roskamp Institute Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rock Creek Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on
      blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's
      Disease (AD) in subjects with mild to moderate AD.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administrative status of active ingredient anatabine
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing adverse effects when using the supplement</measure>
    <time_frame>3 months</time_frame>
    <description>Collected data on the numbers and types of adverse effects among subject individuals with mild to moderate Alzheimer's disease (AD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured changes in blood markers of AD</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in blood levels of amyloid beta (Aβ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in global or functional measures of AD in subjects during the course of the study</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in subject's scores in global and functional measures of AD during the course of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Dietary Supplement: Anatabloc(R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, as mint-flavored lozenge, to be taken 2-3 times each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Anatabloc(R)</intervention_name>
    <description>Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day</description>
    <arm_group_label>Dietary Supplement: Anatabloc(R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 65 years old.

          -  Have a diagnosis of probable AD or a concurrent diagnosis of probable AD and possible
             or probable vascular dementia.

          -  Score 16 or more on the Mini-Mental State Examination (MMSE).

          -  Otherwise stable medical history and general health.

          -  Weigh between 45 kg and 120 kg inclusive.

        Exclusion Criteria:

          -  Have contra-indications, allergy, or sensitivity to the study products or their
             components.

          -  Be currently taking any of the following medications: systemic (oral or injectable)
             glucocorticoids; interferon-alpha; anti-CD20 antibody (e.g., rituximab); or
             anti-CTLA-4 antibody (e.g., ipilimumab).

          -  Be a current smoker or smokeless tobacco user.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A Keegan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roskamp Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roskamp Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2012</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Dietary Supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

